For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
Blog
Congress shouldn’t rely on incomplete FTC PBM study
Lawmakers are making a last-minute push to regulate the practices of pharmacy benefit managers (PBMs) during the lame duck session. However, it would be a…
Wall Street Journal
A Thumb on the Scale for Wegovy
The Biden administration announced one more bit of executive overreach on its way out the door. On Nov. 26, the Centers for Medicare and Medicaid…
National Review
Telehealth Is Less Promising Than It First Seemed
A key issue facing Congress in its postelection, “lame duck” session is whether to extend regulatory flexibilities expiring at year end that make telehealth services more…
Search Posts
New York Post
The numbers prove Cuomo’s lockdowns hurt NYers on EVERY metric — while Florida flourished
What a difference a few years make. In 2020, the mainstream media lauded Gov. Andrew Cuomo for his strong but compassionate COVID-19 leadership. He won a…
Fox News
DeSantis’s Florida beats Newsom’s California, again. Here’s the comparison
The COVID-19 pandemic elicited unprecedented government interventions into American life. Yet, the stringency and duration of government measures varied considerably across the U.S. …
Study
Freedom Wins
ABOUT THE AUTHORS Joel M. Zinberg, M.D., J.D. is the Director the Public Health and American Well-Being Initiative at Paragon Health Institute, and a senior…
Blog
Fauci Failure to Acknowledge Limited Vaccine Protection Undermines Faith in Government Advice
In a recent article Dr. Anthony Fauci acknowledged that, from the beginning of the pandemic, there was good reason to believe that vaccines against…
Regulatory Transparency Project
AUDIO: Explainer Episode 48 – The FDA & the Practice of Medicine: Possible Regulation of Off-Label Prescriptions
Senior Fellow Joel Zinberg joins the Regulatory Transparency Project to discuss possibly regulation of off-label prescriptions: On December 29, 2022, President Biden signed the Consolidated Appropriations…
Citation
FDA’s Medical Interference, Time for ESG Antitrust Action and other commentary
Libertarian: FDA’s Medical Interference The Wall Street Journal quoted Joel Zinberg on FDA banning practices: “Secreted within the 2023 omnibus appropriations…